Skip to Main Content

Paper Details

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review.
0
2023
ACS, PCSK9, PCSK9i, acute myocardial infarction, alirocumab, atherosclerotic cardiovascular disease, monoclonal PCSK9 antibodies evolocumab, myocardial infarction, patients, stroke
Author NameAffiliation
Robert P GiuglianoBrigham and Women's Hospital
  • 1 - 1

Datasets

Release 1.2